Raleigh, NC-based BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on the development and commercialization of treatments in the areas of pain management and drug addiction.
The company utilizes its novel, patented and proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology for the development of products. The company’s portfolio currently consists of three FDA-approved products – Onsolis (breakthrough cancer pain in opioid-tolerant adult patients), Bunavail (opioid dependence) and Belbuca (management of pain severe enough to require daily, round-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate).
Belbuca was launched by its partner Endo International plc in Feb 2016. Meanwhile, BioDelivery is currently working on driving Bunavail sales.
In this scenario, investor focus remains on the sales ramp up of Bunavail and Belbuca and other pipeline related updates apart from the usual top-and bottom-line numbers.
BioDelivery’s performance so far has been disappointing with the company beating expectations in none of the last four quarters with an average miss of 19.59%.
Currently, BioDelivery has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: BioDelivery’s third-quarter 2016 loss of 30 cents per share is wider than consensus estimates of 26 cents per share.
Revenues: Revenues were above expectations. BioDelivery posted revenues of $3.6 million, compared to our consensus estimate of $3 million which included a one-time recording of $2.5 million for the upfront payment from Collegium Pharmaceutical for the licensing rights to Onsolis in the U.S.
Key Stats: Bunavail prescription sales were relatively unchanged from the prior quarter. The drug, however, saw a 68% increase in sales year over year. The company has strategically consolidated its sales force, which will result in total savings of approximately $20 million through the end of 2017.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on this RDUS earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
Image: Bigstock
BioDelivery (BDSI) Q3 Loss Wider Than Expected; Revenue Beat
Raleigh, NC-based BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on the development and commercialization of treatments in the areas of pain management and drug addiction.
The company utilizes its novel, patented and proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology for the development of products. The company’s portfolio currently consists of three FDA-approved products – Onsolis (breakthrough cancer pain in opioid-tolerant adult patients), Bunavail (opioid dependence) and Belbuca (management of pain severe enough to require daily, round-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate).
Belbuca was launched by its partner Endo International plc in Feb 2016. Meanwhile, BioDelivery is currently working on driving Bunavail sales.
In this scenario, investor focus remains on the sales ramp up of Bunavail and Belbuca and other pipeline related updates apart from the usual top-and bottom-line numbers.
BioDelivery’s performance so far has been disappointing with the company beating expectations in none of the last four quarters with an average miss of 19.59%.
Currently, BioDelivery has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: BioDelivery’s third-quarter 2016 loss of 30 cents per share is wider than consensus estimates of 26 cents per share.
Revenues: Revenues were above expectations. BioDelivery posted revenues of $3.6 million, compared to our consensus estimate of $3 million which included a one-time recording of $2.5 million for the upfront payment from Collegium Pharmaceutical for the licensing rights to Onsolis in the U.S.
Key Stats: Bunavail prescription sales were relatively unchanged from the prior quarter. The drug, however, saw a 68% increase in sales year over year. The company has strategically consolidated its sales force, which will result in total savings of approximately $20 million through the end of 2017.
BIODELIVERY SCI Price and EPS Surprise
BIODELIVERY SCI Price and EPS Surprise | BIODELIVERY SCI Quote
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on this RDUS earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>